2. Search Result
Search Result
Results for "

thromboembolic diseases

" in MedChemExpress (MCE) Product Catalog:

22

Inhibitors & Agonists

2

Biochemical Assay Reagents

1

Peptides

1

Inhibitory Antibodies

3

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-137431A
    (R)-Asundexian

    (R)-BAY-2433334

    		 Others Cardiovascular Disease
    (R)-Asundexian ((R)-BAY-2433334) is the enantiomer of Asundexian (HY-137431). (R)-Asundexian can be used in studies of cardiovascular disease (especially thrombotic or thromboembolic disease), edema, and ophthalmic disease .
    (R)-Asundexian
  • HY-101918
    DS-1040 Tosylate

    		Others Cardiovascular Disease
    DS-1040 Tosylate is an orally active, selective inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) with IC50s of 5.92 nM and 8.01 nM for human and rat TAFIa. DS-1040 Tosylate is a fibrinolysis enhancer for thromboembolic diseases .
    DS-1040 Tosylate
  • HY-100655
    O-Desmethyl apixaban

    		Drug Metabolite Cardiovascular Disease
    O-Desmethyl apixaban is a metabolite of Apixaban (BMS-562247-01) . Apixaban is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively .
    O-Desmethyl apixaban
  • HY-163348
    FXIIa-IN-4

    		Factor Xa Thrombin Cardiovascular Disease
    FXIIa-IN-4 (compound 22) is a potent, selective human FXIIa inhibitor with the IC50 of 0.032 μM, 0.30 μM, ＞50 μM for FXIIa, thrombin and FXIa, respectively. FXIIa-IN-4 can be used for study of anticoagulant .
    FXIIa-IN-4
  • HY-50667
    Apixaban
    Maximum Cited Publications
    11 Publications Verification

    BMS-562247-01

    		 Factor Xa Cardiovascular Disease Cancer
    Apixaban (BMS-562247-01) is a highly selective, reversible and orally active inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively . Apixaban is in development for the prevention and treatment of various thromboembolic diseases .
    Apixaban
  • HY-P99415
    Abelacimab

    MAA868

    		 Factor Xa Cardiovascular Disease
    Abelacimab (MAA868) is a fully human IgG1 monoclonal antibody that binds with high affinity to the catalytic structural domain of FXI and locks it in the zymogen conformation, thereby preventing its activation by FXIIa or thrombin. Abelacimab can be used in thromboembolic disease studies .
    Abelacimab
  • HY-100655R
    O-Desmethyl apixaban (Standard)

    		Drug Metabolite Cardiovascular Disease
    O-Desmethyl apixaban (Standard) is the analytical standard of O-Desmethyl apixaban. This product is intended for research and analytical applications. O-Desmethyl apixaban is a metabolite of Apixaban (BMS-562247-01) . Apixaban is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively .
    O-Desmethyl apixaban (Standard)
  • HY-W091734
    Methyl 4-iodo-L-phenylalaninate hydrochloride

    		Amino Acid Derivatives Cardiovascular Disease Neurological Disease
    Methyl 4-iodo-L-phenylalaninate hydrochloride is a Phenylalaninate derivative. Methyl 4-iodo-L-phenylalaninate hydrochloride can be used for the preparation of factor XI modulators used in the research of thrombotic and thromboembolic. Methyl 4-iodo-L-phenylalaninate hydrochloride can also be used for the synthesis of compounds for the research of amyloid-related diseases, such as Alzheimer’s disease .
    Methyl 4-iodo-L-phenylalaninate hydrochloride
  • HY-125615
    DMP 728 methanesulfonate

    		Glycoprotein VI Cardiovascular Disease Others
    DMP 728 methanesulfonate is a platelet glycoprotein (GP) IIb/IIIa receptor antagonist. DMP 728 methanesulfonate shows dose-dependent antiplatelet and antithrombotic effects. DMP 728 methanesulfonate can be used in the study of effective antithrombotic agents in thromboembolic diseases of coronary and peripheral arteries .
    DMP 728 methanesulfonate
  • HY-50667R
    Apixaban (Standard)

    		Factor Xa Cardiovascular Disease Cancer
    Apixaban (Standard) is the analytical standard of Apixaban. This product is intended for research and analytical applications. Apixaban (BMS-562247-01) is a highly selective, reversible and orally active inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively . Apixaban is in development for the prevention and treatment of various thromboembolic diseases .
    Apixaban (Standard)
  • HY-163347
    FXIIa-IN-3

    		Factor Xa Cardiovascular Disease
    FXIIa-IN-3 (Compound 8) is a potent and selective Factor XIIa (FXIIa) inhibitor, with an IC50 of 0.045 μM. FXIIa-IN-3 also exhibits a substantial margin of selectivity against related serine proteases, including FXIa, FXa, and FIXa. FXIIa-IN-3 can be used for the research of thromboembolic diseases .
    FXIIa-IN-3
  • HY-10264
    Edoxaban
    5+ Cited Publications

    DU-176

    		 Factor Xa Thrombin Cardiovascular Disease Cancer
    Edoxaban (DU-176b) is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Ki values of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban can be used in preventing thromboembolic disease research .
    Edoxaban
  • HY-10264B
    Edoxaban tosylate monohydrate
    5+ Cited Publications

    DU-176b monohydrate

    		 Factor Xa Thrombin Cardiovascular Disease Cancer
    Edoxaban (DU-176b) monohydrate is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Kis of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban monohydrate exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban monohydrate can be used for preventing thromboembolic disease research .
    Edoxaban tosylate monohydrate
  • HY-10264A
    Edoxaban tosylate
    5+ Cited Publications

    DU-176b

    		 Factor Xa Thrombin Cardiovascular Disease Cancer
    Edoxaban (DU-176b) tosylate is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Kis of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban tosylate exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban tosylate can be used for preventing thromboembolic disease research .
    Edoxaban tosylate
  • HY-10264C
    Edoxaban hydrochloride

    DU-176 hydrochloride

    		 Factor Xa Thrombin Cardiovascular Disease Cancer
    Edoxaban (DU-176b) hydrochloride is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Ki values of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban hydrochloride exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban hydrochloride can be used for preventing thromboembolic disease research .
    Edoxaban hydrochloride
  • HY-50667S1
    Apixaban-d3

    BMS-562247-01-d3

    		 Isotope-Labeled Compounds Factor Xa Others
    Apixaban-d3 (BMS-562247-01-d3) is the deuterium labeled Apixaban (HY-50667) . Apixaban (BMS-562247-01) is a highly selective, reversible and orally active inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively . Apixaban is in development for the prevention and treatment of various thromboembolic diseases .
    Apixaban-d3
  • HY-150682
    FXIa-IN-9

    		Factor Xa Cardiovascular Disease
    FXIa-IN-9 (compound 3f) is a potent and selective FXIa inhibitor. FXIa-IN-9 can bind with FXIa and form hydrogen bond (human FXIa Ki: 0.17 nM, rabbit FXIa Ki: 0.5 nM). FXIa-IN-9 also has anticoagulant activity, and can be used in the research of thromboembolic diseases such as atrial fibrillation, stroke, myocardial infarction, deep vein thrombosis, and pulmonary embolism .
    FXIa-IN-9
  • HY-10264R
    Edoxaban (Standard)

    		Factor Xa Thrombin Cardiovascular Disease Cancer
    Edoxaban (Standard) is the analytical standard of Edoxaban. This product is intended for research and analytical applications. Edoxaban (DU-176b) is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Ki values of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban can be used in preventing thromboembolic disease research .
    Edoxaban (Standard)
  • HY-D0837
    Imidazole
    2 Publications Verification

    Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene

    		 Ser/Thr Protease Thrombopoietin Receptor Neurological Disease Inflammation/Immunology
    Imidazole (Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene) is a heterocyclic aromatic compound. Imidazole bearing molecules have been used as corrosion, acetylcholinesterase (AChEI) and xanthine oxidase (XO) inhibitors, performing biological activities such as antifungal, antituberculosis, anti-inflammatory, antioxidant, and analgesic, amongst many others. Imidazole inhibits the enzymatic conversion of the endoperoxides (PGG2 and PGH2) to thromboxane A2 by platelet microsomes. Imidazole derivatives exhibits inhibition on SARS-CoV-2 3CL Pro enzyme, which is promising for research in the field of Alzheimer’s disease, gout, COVID-19 and thrombo-embolic disease .
    Imidazole
  • HY-10264S
    Edoxaban-d6

    DU-176-d6

    		 Factor Xa Thrombin Cardiovascular Disease
    Edoxaban-d6 is deuterium labeled Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention. Edoxaban is also a weak inhibitor of thrombin and factor IXaβ (FIXa), with Kis of 6.00 μM and 41.7 μM, respectively, exhibits >10000-fold selectivity for FXa. Edoxaban has antithrombotic properties and has potential for thromboembolic diseases treatment .
    Edoxaban-d6
  • HY-D0837R
    Imidazole (Standard)

    		Ser/Thr Protease Thrombopoietin Receptor Neurological Disease Inflammation/Immunology
    Imidazole (Standard) is the analytical standard of Imidazole. This product is intended for research and analytical applications. Imidazole (Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene) is a heterocyclic aromatic compound. Imidazole bearing molecules have been used as corrosion, acetylcholinesterase (AChEI) and xanthine oxidase (XO) inhibitors, performing biological activities such as antifungal, antituberculosis, anti-inflammatory, antioxidant, and analgesic, amongst many others. Imidazole inhibits the enzymatic conversion of the endoperoxides (PGG2 and PGH2) to thromboxane A2 by platelet microsomes. Imidazole derivatives exhibits inhibition on SARS-CoV-2 3CLPro enzyme, which is promising for research in the field of Alzheimer’s disease, gout, COVID-19 and thrombo-embolic disease .
    Imidazole (Standard)
  • HY-W699983
    Imidazole-15N2

    Glyoxaline-15N2; 1,3-Diaza-2,4-cyclopentadiene-15N2

    		 Isotope-Labeled Compounds Thrombopoietin Receptor Ser/Thr Protease Neurological Disease Inflammation/Immunology
    Imidazole- 15N2 (Glyoxaline- 15N2) is 15N labeled Imidazole. Imidazole (Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene) is a heterocyclic aromatic compound. Imidazole bearing molecules have been used as corrosion, acetylcholinesterase (AChEI) and xanthine oxidase (XO) inhibitors, performing biological activities such as antifungal, antituberculosis, anti-inflammatory, antioxidant, and analgesic, amongst many others. Imidazole inhibits the enzymatic conversion of the endoperoxides (PGG2 and PGH2) to thromboxane A2 by platelet microsomes. Imidazole derivatives exhibits inhibition on SARS-CoV-2 3CL Pro enzyme, which is promising for research in the field of Alzheimer’s disease, gout, COVID-19 and thrombo-embolic disease .
    Imidazole-15N2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: